24. April 2025

New Bioactive Compound for Difficult-to-Treat Allergies New Bioactive Compound for Difficult-to-Treat Allergies

University of Bonn-guided study leads to the discovery of a promising receptor blocker

Irritable bowel syndrome, chronic itching, asthma and migraine are in many cases hard-to-treat conditions. They have in common that they are triggered by an excessive immune response—which in severe cases can be life-threatening. A team of researchers led by the University of Bonn has now identified a promising bioactive compound that could effectively reduce symptoms and slash fatality risk. The compound blocks a receptor on certain defense cells, thus preventing a derailed immune response. The study findings have been published in the journal Signal Transduction and Targeted Therapy.

Mast cells are packed with substances - which they release upon coming into contact with allergens (above). Blocking the responsible receptor prevents release, thus hindering a strong inflammatory reaction (below).
Mast cells are packed with substances - which they release upon coming into contact with allergens (above). Blocking the responsible receptor prevents release, thus hindering a strong inflammatory reaction (below). © Image: Dr. Müller’s working group/University of Bonn
Download all images in original size The impression in connection with the service is free, while the image specified author is mentioned.
Please fill out this field using the example format provided in the placeholder.
The phone number will be handled in accordance with GDPR.

Ghazl Al Hamwi et. al.: Subnanomolar MAS-related G protein-coupled receptor-X2/B2 (MRGPRX2/B2) antagonists with efficacy in human mast cells and disease models; Signal Transduction and Targeted Therapy; DOI: 10.1038/s41392-025-02209-82

Wird geladen